Key Points:
• Attovia Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) to raise up to $100 million through an initial public offering (IPO).
• The clinical-stage biotechnology company is developing biologic therapies for immune-mediated diseases using its proprietary ATTOBODY nanobody platform.
• Its lead drug candidate, ATTO-1310, has completed Phase 1 dosing, while two additional pipeline programs are advancing toward clinical trials.
• The company plans to list on the Nasdaq under the ticker symbol ATTO.
Attovia Therapeutics Pursues Public Listing
Attovia Therapeutics has filed for an estimated $100 million IPO, seeking additional capital to accelerate the clinical development of its pipeline of biologic therapies targeting immune-mediated diseases. The offering marks another notable biotechnology listing as investors continue to evaluate innovative drug developers focused on autoimmune and inflammatory disorders.
Headquartered in San Carlos, California, Attovia Therapeutics was founded in 2022 and operates as a clinical-stage biopharmaceutical company. While it has not yet commercialized any products, the company is building a portfolio of next-generation biologic therapies designed to address diseases with significant unmet medical needs.
The company confidentially submitted its IPO registration in December 2025 and now intends to trade on the Nasdaq Stock Market under the ticker ATTO.
Proprietary ATTOBODY Platform
Attovia’s drug development strategy is centered on its proprietary ATTOBODY platform, a biparatopic nanobody-based technology licensed from Alamar Biosciences. The platform is designed to create highly targeted biologic therapies capable of binding multiple disease-related pathways simultaneously, potentially improving efficacy while maintaining favorable safety profiles.
Unlike traditional monoclonal antibodies, nanobody-based therapeutics are significantly smaller molecules that may offer advantages in tissue penetration, manufacturing efficiency, and multi-target drug design.
The company’s pipeline currently focuses on inflammatory and immune-mediated diseases, including dermatological conditions and inflammatory bowel disease.
Lead Candidate Advances Through Phase 1
Attovia’s most advanced drug candidate is ATTO-1310, which targets interleukin-31 (IL-31), a cytokine closely associated with chronic itching and inflammatory skin diseases.
The therapy has successfully completed Phase 1 dosing in both healthy volunteers and patients suffering from chronic pruritus and atopic dermatitis. Completion of early-stage dosing represents an important milestone as the company prepares for additional clinical development designed to evaluate efficacy in larger patient populations.
Chronic pruritus and atopic dermatitis remain significant therapeutic markets where demand continues to grow for treatments capable of providing durable symptom relief with improved safety profiles.
Expanding Pipeline Targets Multiple Immune Disorders
Beyond its lead asset, Attovia is developing additional multi-target biologics aimed at complex immune-mediated diseases.
ATTO-2306 is a bispecific therapy targeting both IL-13 and IL-31 for atopic dermatitis and related inflammatory skin disorders. The candidate is currently completing IND-enabling studies, with a Phase 1 clinical trial expected during the first half of 2027.
The company’s third major candidate, ATTO-1091, is a trispecific biologic targeting TL1A, IL-23, and integrin α4β7 for the treatment of inflammatory bowel disease (IBD). This program is also progressing through IND-enabling studies before entering human clinical testing.
The multi-target approach reflects a growing industry trend toward simultaneously blocking several inflammatory pathways to improve treatment outcomes in chronic autoimmune diseases.
Financial Position
As a clinical-stage biotechnology company, Attovia has not generated revenue from commercial product sales. The company reported approximately $1 million in total revenue for the twelve months ended March 31, 2026, primarily reflecting collaboration or licensing-related activities rather than marketed therapies.
Like many early-stage biotechnology firms, Attovia remains dependent on external financing to fund research, clinical development, regulatory activities, and future commercialization efforts.
Proceeds from the IPO are expected to support continued advancement of its clinical pipeline and platform technologies.
IPO Details
Attovia Therapeutics plans to raise up to $100 million through its initial public offering, although final pricing and the number of shares to be sold have not yet been announced.
The offering is being led by an experienced syndicate of investment banks, including Morgan Stanley, Leerink Partners, Citi, RBC Capital Markets, and LifeSci Capital as joint bookrunners.
Outlook
The proposed IPO provides Attovia Therapeutics with an opportunity to secure the capital necessary to advance several promising immune disease therapies through clinical development. While the company remains in the early stages of commercialization with no approved products, its proprietary ATTOBODY platform and diversified pipeline position it within one of biotechnology’s most active therapeutic areas.
Investor attention will likely focus on the future clinical progress of ATTO-1310, the advancement of its bispecific and trispecific programs, and management’s ability to demonstrate differentiated efficacy in increasingly competitive markets for autoimmune and inflammatory disease treatments.
